David B. Solit
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
Papers in
-
- Melanoma and MAPK Pathways 43
- Heat shock proteins research 26
- Oncology 123
- Colorectal Cancer Treatments and Studies 35
- HER2/EGFR in Cancer Research 23
- Co-authors
- Neal Rosen (75 shared papers)Michael F. Berger (126 shared papers)Andrea Basso (8 shared papers)Qing‐Bai She (6 shared papers)Christine A. Pratilas (16 shared papers)Gabriela Chiosis (8 shared papers)Barry S. Taylor (32 shared papers)José Baselga (13 shared papers)
- Journals
- Journal of Clinical Oncology (121 papers)Cancer Research (37 papers)Clinical Cancer Research (30 papers)The Journal of Urology (13 papers)Cancer (11 papers)
- Partner nations
- United StatesSpainCanada
In The Last Decade
David B. Solit
351 papers receiving 27.4k citations
David B. Solit's Hit Papers
Peers
Comparison fields: 5 of 166
- Oncology 9.4k
- Cancer Research 4.2k
- Molecular Biology 15.0k
- Pathology and Forensic Medicine 2.9k
- Pulmonary and Respiratory Medicine 4.7k
Countries citing papers authored by David B. Solit
This map shows the geographic impact of David B. Solit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Solit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Solit more than expected).
Fields of papers citing papers by David B. Solit
This network shows the impact of papers produced by David B. Solit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Solit. The network helps show where David B. Solit may publish in the future.
Co-authors
The 25 scholars most cited alongside David B. Solit, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 376 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Hit paper breakdown → | 2006 | 2110 |
| 2 | Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Hit paper breakdown → | 2012 | 1433 |
| 3 | BRAF mutation predicts sensitivity to MEK inhibition Hit paper breakdown → | 2005 | 1064 |
| 4 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy Hit paper breakdown → | 2017 | 784 |
| 5 | Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer Hit paper breakdown → | 2018 | 617 |
| 6 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes Hit paper breakdown → | 2017 | 545 |
| 7 | Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function Hit paper breakdown → | 2002 | 537 |
| 8 | Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity Hit paper breakdown → | 2015 | 505 |
| 9 | Genome Sequencing Identifies a Basis for Everolimus Sensitivity Hit paper breakdown → | 2012 | 504 |
| 10 | 2009 | 473 | |
| 11 | 2009 | 443 | |
| 12 | Tumor adaptation and resistance to RAF inhibitors Hit paper breakdown → | 2013 | 437 |
| 13 | Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention Hit paper breakdown → | 2018 | 389 |
| 14 | Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers Hit paper breakdown → | 2018 | 381 |
| 15 | 2015 | 374 | |
| 16 | 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. | 2002 | 373 |
| 17 | Genome doubling shapes the evolution and prognosis of advanced cancers Hit paper breakdown → | 2018 | 358 |
| 18 | 2010 | 358 | |
| 19 | 2005 | 358 | |
| 20 | 2017 | 357 |
About David B. Solit
David B. Solit is a scholar working on Molecular Biology, Oncology, Surgery, Pulmonary and Respiratory Medicine and Cancer Research, having authored 376 papers that have together received 28.0k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (80 papers), Cancer Genomics and Diagnostics (74 papers), Melanoma and MAPK Pathways (43 papers), Lung Cancer Treatments and Mutations (36 papers), Colorectal Cancer Treatments and Studies (35 papers), Genetic factors in colorectal cancer (30 papers), Heat shock proteins research (26 papers) and HER2/EGFR in Cancer Research (23 papers). The work is most often cited by research in Oncology (9.4k citations), Cancer Research (4.2k citations), Molecular Biology (15.0k citations), Pathology and Forensic Medicine (2.9k citations) and Pulmonary and Respiratory Medicine (4.7k citations). David B. Solit has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Neal Rosen, Michael F. Berger, Andrea Basso, Qing‐Bai She, Christine A. Pratilas, Gabriela Chiosis, Barry S. Taylor, José Baselga, Qing Ye and Marc Ladanyi. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, The Journal of Urology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.